OUR MISSION
Improve assessment of individual patient’s responses and toxicity profiles to specific therapies, to radically change the meaning of personalized medicine.
Our cutting-edge genetic research discovered a new class of genetic biomarkers that can dramatically change personalized treatment.
MiraDx partners with universities and pharmaceutical companies to utilize our unique genetic research to help better treat cancer. MiraDx was co-founded by Joanne Weidhaas, M.D., Ph.D. and Frank Slack, Ph.D. whose cutting-edge genetic research discovered this new class of genetic biomarkers.
Joanne Weidhaas, M.D., Ph.D., M.S.M
FOUNDER
Joanne is co-founder of MiraDx and Professor at the David Geffen School of Medicine at UCLA and head of translation research, in the Department of Therapeutic Radiology. Her pioneering research led to the co-discovery of the KRAS-variant, a strong predictor of cancer risk, tumor biology and treatment response. Her passion for empowering individuals to take charge of their health led her to found MiraDx, a genomics company dedicated to giving people and their doctors actionable information to better treat cancer. Joanne completed her oncology training at Memorial Sloan-Kettering Cancer Center in New York City and previously served as the Chief of the Breast Cancer Radiation Service at Yale Cancer Center and the Section Chief, Breast Cancer, Yale Cancer Center. She took a sabbatical while at Yale and completed a MBM at Stanford University. She has recently moved to UCLA as Division Head, Translational Research. Her dual role as a clinician and researcher enables her to apply genetic breakthroughs to the benefit of her patients. She currently lives in the LA area, with her husband and three children.
Frank Slack, Ph.D.
Co-Founder
Frank is a co-founder of MiraDx and currently the Shields Warren Mallinckrodt Professor, Department of Pathology, and Director of the Institute for RNA Medicine, at BIDMC.
Andrew J. Weidhaas
Board of Directors
A.J. is a partner in and co-chair of Goodwin Procter’s Private Equity Group, as well as a member of its Technology Companies Practice. He specializes in private equity and
Mary Lake Polan, M.D., Ph.D., MPH
Board of Directors
Dr. Polan is an Adjunct Professor in the Department of Obstetrics and Gynecology and Reproductive Sciences at Columbia University School of Medicine as well as Chair Emeritus of
Roy Vagelos M.D.
Medical Advisory Board
Dr. Vagelos is the Chair of the Columbia University School of Physicians and Surgeons Development Campaign and of the board of directors of Regeneron Pharmaceuticals. He is former CEO, Chairman and Senior Vice President for Research of Merck.
Richard Gatti, MD, Ph.D.
Laboratory Director, Advisor
Dr. Gatti is an emeritas distinguished professor of Pathology and Laboratory Medicine at UCLA. He is a world-renowned molecular geneticist and immunologist and a pioneer in transplantation medicine. Dr. Gatti specializes in Ataxia Telangiectasia,
Sara Rosenthal
Advisor, Women’s Health
Sara began her career in the fields of health policy research and healthcare management consulting, with a specific interest in women’s health. After earning her master’s degree in business administration from the Stanford Graduate School of Business,
Jean Reiss
Clinical Laboratory Scientist
Jean Reiss is currently working at MiraDx Inc. as CLS since MiraDx moved to California in July, 2015 responsible for assay validation, clinical sample testing and required quality controls procedures.
Prior to MiraDx Inc. Jean Reiss retired in 2014 after 22 years of services from Molecular Diagnostics Laboratories